|
⚲
|
| Keyboard |
| ADAR1 Capital Management LLC
✚
|
|
|---|---|
| CRD # | 299694 |
| SEC # | 801-130082 |
| CIK # | 0001940272 |
| AUM | 1,675.1 M (2026-03-31) |
| Employees | 11 (64% Investors, 0% Brokers) |
| Phone | 512-254-3790 |
| Address | 3503 Wild Cherry Drive Austin, TX 78738 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| In the News | |
|---|---|
| Fri, 15 May 2026 | Adar1 Capital Management buys $1.11m of Rallybio (RLYB) stock — Investing.com |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Abivax Sa | 160.1 | ||
| Protagonist Therapeutics Inc | 104.8 | ||
| Roivant Sciences Ltd | 91.0 | ||
| Health Sciences Acquisitions Corp | 66.5 | ||
| Cytokinetics Inc | 41.7 | ||
| Crinetics Pharmaceuticals Inc | 41.4 | ||
| Denali Therapeutics Inc | 35.9 | ||
| Beam Therapeutics Inc | 34.5 | ||
| Zai Lab Ltd | 26.8 | ||
| Septerna Inc | 26.2 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | ADAR1 SPV I LP | [2025-03-31] | 296.9 M | 112.7 M |
| Filed 2025-08-08 (D/A) · Exemption 506(b) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | ADAR1 Partners LP | [2024-03-28] | 296.9 M | 1,179.9 M |
| Filed 2025-08-08 (D/A) · Exemption 506(b) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 8 | 1,675.1 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 8 | 1,675.1 |
| By Discretionary | ||
| Discretionary | 8 | 1,675.1 |
| Non-Discretionary | 0 | 0.0 |
| Total | 8 | 1,675.1 |
| By Non-United States Persons | ||
| Non-United States Persons | 656.9 | |
| United States Persons | 1,018.3 | |
| Total | 8 | 1,675.1 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Daniel Schneeberger | Director | 3 | 2 | |
| Adar1 Capital Management LLC | Executive Officer | 3 | 2 | |
| Stephen Scipione | Director | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001940272] | |
| 3 | [0001940272] | |
| 4 | [0001940272] | |
| SC 13D | [0001940272] | |
| SC 13G | [0001940272] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.5B |
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300YNEBMYE1SWQH64 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Keros Therapeutics Inc KROS
Common Stock
|
2025-10-15 | Sell | 254,669 | $17.75 | 4,520,375 |
|
Keros Therapeutics Inc KROS
Common Stock
|
2025-10-15 | Sell | 4,391,237 | $17.75 | 77,944,457 |
|
Keros Therapeutics Inc KROS
Common Stock
|
2025-10-15 | Sell | 743,358 | $17.75 | 13,194,604 |
|
Keros Therapeutics Inc KROS
Put Option (right to sell) · derivative
|
2025-06-20 | Option exercise | 2 | $0.00 | |
|
Keros Therapeutics Inc KROS
Put Option (right to sell) · derivative
|
2025-06-20 | Option exercise | 14 | $0.00 | |
|
Keros Therapeutics Inc KROS
Put Option (right to sell) · derivative
|
2025-06-20 | Option exercise | 1 | $0.00 | |
|
Keros Therapeutics Inc KROS
Common Stock
|
2025-06-20 | Option exercise | 200 | $70.00 | 14,000 |
|
Keros Therapeutics Inc KROS
Common Stock
|
2025-06-20 | Option exercise | 100 | $60.00 | 6,000 |
|
Keros Therapeutics Inc KROS
Common Stock
|
2025-06-20 | Option exercise | 1,400 | $70.00 | 98,000 |
|
Keros Therapeutics Inc KROS
Put Option (obligation to buy) · derivative
|
2025-05-16 | E | 836 | $0.00 | |
|
Keros Therapeutics Inc KROS
Put Option (obligation to buy) · derivative
|
2025-05-16 | E | 300 | $0.00 | |
|
Keros Therapeutics Inc KROS
Put Option (obligation to buy) · derivative
|
2025-05-16 | E | 178 | $0.00 | |
|
Keros Therapeutics Inc KROS
Cash-Settled Total Return Swaps · derivative
|
2025-04-09 | Other | 500,000 | ||
|
Keros Therapeutics Inc KROS
Common Stock
|
2025-04-09 | Buy | 325,000 | $9.86 | 3,204,500 |
|
Keros Therapeutics Inc KROS
Common Stock
|
2025-04-09 | Buy | 500,000 | $10.33 | 5,165,000 |
|
Keros Therapeutics Inc KROS
Cash-Settled Total Return Swaps · derivative
|
2025-04-09 | Other | 325,000 | ||
|
Keros Therapeutics Inc KROS
Cash Settled Total Return Swaps · derivative
|
2025-04-09 | Other | 74,333 | ||
|
Keros Therapeutics Inc KROS
Common Stock
|
2025-04-09 | Buy | 74,333 | $10.33 | 767,860 |
|
Keros Therapeutics Inc KROS
Common Stock
|
2025-04-09 | Buy | 18,560 | $9.40 | 174,464 |
|
Keros Therapeutics Inc KROS
Common Stock
|
2025-04-09 | Buy | 16,365 | $9.40 | 153,831 |
| showing 20 of 23 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Prescott General Partners LLC
✚
|
FL | 1,694.9 M |
|
Parsifal Capital Management LP
✚
|
CT | 1,694.4 M |
|
Affinity Asset Advisors LLC
✚
|
NY | 1,691.1 M |
|
Quantitative Investment Management LLC
✚
|
VA | 1,670.6 M |
|
FORA Capital LLC
✚
|
FL | 1,665.4 M |
|
Philosophy Capital Management LLC
✚
|
CA | 1,663.1 M |
|
Deltroit Asset Management UK LLP
✚
|
1,655.8 M | |
|
Richbrook Advisors LP
✚
|
NY | 1,652.9 M |
|
Bain Capital Partnership Strategies LP
✚
|
MA | 1,652.2 M |
|
Park Presidio Capital LLC
✚
|
CA | 1,647.5 M |